Invasive aspergillosis (IA) is associated with a high morbidity and mortality. Since Aspergillus species are usually not cultured in these patients, presumptive diagnosis of IA is more commonly based on galactomannan (GM) detection. Several factors are known to cause false-positive results in the GM test, but little is known on the influence of pre-analytical variables interfering on the test. Here we studied the influence of temperature and sample storage duration in GM results, using samples known to be negative and positive (spiked) for GM. We also evaluated the effect of hemolysis and hyperbilirubinemia on GM optical indexes. We found no influence of storage time (up to 96 h) and temperatures (refrigerated vs. RT) on GM results. However, bilirubin (P = .022) and haemoglobin (P = .003) content influenced GM readings in samples known for being GM positive and negative at baseline, respectively. We conclude that the Platelia GM test does not suffer major influence of pre-analytical variables such as storage conditions, and low levels of hemolysis and hyperbilirubinemia. Nonetheless, massive haemolysis seems to interfere with GM readings in GM-negative samples, and high levels of bilirubin can affect GM readings in samples that are positive for GM at baseline. These findings may facilitate logistics and the implementation of standard operational procedures in clinical laboratories.
Introduction
Invasive aspergillosis (IA) is a major cause of morbidity and mortality in immunocompromised patients. 1 Most cases of IA are currently diagnosed based on the detection of galactomannan (GM), 2 a heat-stable and water-soluble polysaccharide that is present in the cell wall of a variety of fungi, particularly Aspergillus species. GM testing in patients with IA is mostly limited by the occurrence of false-positive results, which have been associated with several host-related factors, including antibiotic use, mucositis, dietary factors, and dialysis, as well as cross-reaction with other fungi. 3, 4 Limited information is available on the importance of . In each analysis were performed GM optical density determination, lactate dehydrogenase, hemoglobin, and total bilirubin.
pre-analytical variables as a potential cause of false-positive serum GM results. Pre-analytical variables are known to closely relate to the performance of laboratory tests. One of the most cited interfering agents is hemolysis, which affects about 3% of all laboratory samples in clinical laboratories. [5] [6] [7] This may be related to a clinical and pathological condition, errors in the collection procedure, processing, transportation, or inappropriate sample storage. [8] [9] [10] In an attempt to study the potential impact of pre-analytical variables as a cause of false-positive GM result, here we investigated the effect of different storage conditions, impact of haemolysis and hyperbilirubinemia on GM readings.
Methods
Seven blood collection tubes (2 ml per tube; BD Vacutainer R SST R II Advance R , Becton Dickinson and Company, USA) were taken from adult healthy volunteers (with normal levels of bilirubin and without known haemolytic disease). Serum was separated, and the following analyses were performed, as hemolysis markers: lactate dehydrogenase (LDH), hemoglobin (Hb), and total bilirubin. Samples were stored at two different temperatures: 2-8
• C (refrigerated) and 20-25
• C (room temperature, RT).
Temperatures were controlled by the use of a refrigerator and a microbiological incubator, respectively, and checked periodically with calibrated thermometers. Laboratorial analyses (which also included GM optical density determination) were performed at predetermined times: at baseline (immediately after blood was taken) and after 48 h, 72 h, and 96 h of storage (Fig. 1) . GM was tested using Platelia Aspergillus Ag kit (BioRad, California, USA) following strictly the manufacturer's instructions. Plates were read in iMark TM Microplate Absorbance Reader (Bio-Rad, California, USA). The optical density (OD) results were translated in GM-OD index (GM-ODI), relative to the mean optical density of the cut-off controls (GM-ODI was the result of the sample OD, divided by mean OD of the cut-off control serum). The positivity threshold for GM was ≥0.5, as recommended by the manufacturer. Bilirubin concentrations were determined with a colorimetric test (Bioclin, Belo Horizonte, Brazil) and LDH was determined with kinetic test (Bioclin, Belo Horizonte, Brazil), both measured in the BS-120 Chemistry Analyzer (Mindray, Shenzhen, China). Serum Hb was determined using a kit for manual measurement (colorimetric test, Bioclin, Belo Horizonte, Brazil), with later reading in a UV-VIS Spectrophotometer UV-1800 (Shimadzu Corporation, Kyoto, Japan). In order to study the effect of pre-analytical factors in samples known to be positive for GM, half of the samples from healthy volunteers were spiked with 50 μl of a pool of positive GM controls, as follows. In summary, 20 ml of positive controls from the GM kits (Platelia Aspergillus Ag -Bio-Rad, California, USA) were mixed up with 30 μl of an isolated culture of a reference A. fumigatus strain (AF72, kindly provided by David Denning, National Aspergillosis Centre, UK) [previous experiments showed that positive GM controls alone were unable to generate consistently positive GM results, when added to the sera of healthy individuals-GM-ODI of ≤0.40-data not shown]. The mixture was centrifuged at 2500 rpm for 10 minutes, and it was not filtered. This pool allowed generating samples with a constant amount of GM, in an array that was similar to serum. The pool was left with a GM-ODI of >6.9. To prevent external contamination, all procedures were performed in a laminar flow hood.
To evaluate the effect of high concentrations of bilirubin and Hb on positive and negative samples for GM, two concentration curves of these analytics were built, using bilirubin standard (10 mg/dl) and Hb standard (11.6 g/dl) (Bioclin, Belo Horizonte, Brazil). For the construction of bilirubin curves, 6 tubes were successively numbered and received 200 μl of negative serum control (from the GM kit). Then, tubes were organized as followed: Tube 1: 400 μL of sterile saline; Tube 2: 350 μl of saline and 50 μl of bilirubin standard; Tube 3: 300 μl of saline and 100 μl bilirubin; Tube 4: 200 μl of saline and 200 μl of bilirubin; Tube 5: 100 μl of saline and 300 μl of saline and bilirubin; Tube 6: 400 μl of bilirubin. The same curve was performed using 200 μl of positive serum control (from GM kit), resulting in six additional tubes, as before. The final volume of each tube was 600 μl. Of these, 300 μl were used for analysis of GM, and 300 μl were reserved for the determination of bilirubin concentrations. For the Hb curves, we used the same number of tubes and volumes as for bilirubin. However, Hb standards were previously diluted at 1:2, due to their high initial concentration. Experiments to produce each of the four different curves were performed in three different occasions to ensure reproducibility of the results.
Descriptive statistics were used to summarize the data. For statistical analysis, samples from every individual were compared with baseline results (paired samples). Wilcoxon Signed Rank Test was used to test the results in the samples compared with baseline sample from each patient. P values of <.05 were defined as statistically significant based on a two-tailed test. All calculations were carried out using SPSS version 15.0.
This study was approved by ethics committee of the participating institutions, and the volunteers were only included after signing the informed consent form.
Results
A total of 294 serum samples from 42 healthy volunteers were studied. These individuals were mostly women (71.4%), and median age was 23.5 years old (11.25, interquartile range). Among the 21 volunteers included as negative controls, the mean (± standard deviation, SD) of GM-ODI was 0.18 ± 0.07. For the 21 volunteers who had samples spiked with GM/A. fumigatus culture, mean (±SD) GM-ODI was 2.99 ± 1.26.
Regarding samples that were GM negative at baseline, there was no significant difference in GM-ODI in any of the three moments of analysis (48 h, 72 h, and 96 h), in comparison to baseline, regardless of the incubation temperature (Table 1) . However, storing samples at RT resulted in a significant alteration in Hb and bilirubin concentrations, after 72 h and 96 h. LDH values increased significantly over time, regardless of the storage temperature.
For GM-positive samples at baseline there was no significant change in GM-ODI over the periods of study (Table 2 ). However, there was a significant difference in Hb values after 72 h and 96 h, for samples stored at RT. As before, LDH values varied in function of incubation time, in spite of the storage temperature.
Hb studies revealed that hemolysis was more pronounced in samples stored at RT, for both samples that were baseline GM-negative and GM-positive. However, that did not result in significant changes in GM optical indices. Figure 2 shows the influence of Hb and bilirubin in the GM-ODI. Bilirubin curve showed a significantly negative correlation with positive GM-ODI (Spearman correlation coefficient −0.416; P = .022), while Hb had a significantly positive correlation with negative GM-ODI (Spearman correlation coefficient 0.544; P = .003). Still, no significant correlation was found between bilirubin curve and negative GM-ODI (Spearman correlation coefficient −0.191; P = .186) and Hb curve and positive GM-ODI (Spearman correlation coefficient 0.025; P = .461). Thus, high Hb concentrations can increase GM-ODI in samples that were GM-negative by up to 42%, while high bilirubin concentrations can reduce GM-ODI by up to 44%.
Discussion
This is the first study to document the effects of preanalytical variables (hemolysis and hyperbilirubinemia) in serum samples subjected to GM testing. Our data showed that Platelia GM test was highly robust, allowing for the analysis of samples stored for up to 5 days at RT. Yet we observed that the bilirubin and haemoglobin may undergo changes due to storage at RT. Nevertheless, these changes were not biologically significant; that is, they were not able to alter the results of GM. Furthermore, we showed that the presence of Hb and bilirubin may interfere in serum GM-ODI for baseline GM-negative and GM-positive samples, respectively. Few studies have evaluated the short-term stability of samples tested for GM. When evaluating the repeatability of GM results after short-term storage, 11-13 these studies . The y-axis shows GM optical indices (GM-ODI). Legend: (1) Variations in GM-ODI in samples that tested negative for GM at baseline, in relation to hemoglobin concentrations; (2) the same as graph 1 but for samples that were GM-positive at baseline; (3) variations in GM-ODI in negative controls, in relation to bilirubin curve; (4) the same as graph 3 but for samples that were positive for GM at baseline.
found an ODI signal loss in 68-85% of samples. In our study, storage of serum samples at RT for up to 96 h resulted in a decrease of 57% (for GM-negative samples) and 62% (GM-positive samples) in GM-ODI. Despite this reduction, no significant difference in GM results was found in any of the collection times and temperatures. By testing samples with optical indexes very close to positivity (0.5), Johnson et al. found that 65.2% of positive GM samples turned negative, when the test was repeated on the same sample. 13 Loss of signal in the GM test is more common for samples that are close to the cut-off for test positivity (i.e., 0.5) in comparison to samples with high OD-values (≥1.0). 14 Conversely, other studies have evaluated the stability of GM in frozen samples, stored for long periods. In these studies, GM positivity was reduced by 20-68% simply by the effect of long-term storage. [13] [14] [15] [16] [17] However, these data need to be evaluated carefully, as they may be related to low initial GM content. In contrast, other studies found that GM readings remained stable over time. 18, 19 When analyzing the impact of baseline GM status on Hb and bilirubin curves, we noticed that GM samples can to suffer influence of the presence of large amounts of these analytics. Hb concentrations above 0.4 mg/dl can be easily found in samples with high levels of hemolysis. 20 However, in our study these levels were found only in curves artificially created. Due to the influence of haemolysis in the accuracy and reliability of many laboratorial tests, this has been considered the most undesirable and common interference condition in clinical laboratory tests. Free Hb, for example, has a high absorbance at wavelengths ranging between 415 and 570 nm. Thus, their release as a result of the occurrence of haemolysis can potentially increase in the concentration of the analytics measured in this wavelength range due to the increase in measured absorbance of these samples, which can generate false-positive results. 10, 21, 22 Bilirubin is known to interfere with some laboratorial tests, acting as a reducing substance. Assays that utilize oxidase or peroxidase reactions may falsely present with lower results as bilirubin reacts with H 2 O 2 formed in the assay system, being one of the possible mechanisms for their activity as substrates of this enzyme. 22 Therefore, hemolysis and hyperbilirubinemia can directly influence GM results. Although the package insert for Platelia kit informs that values of bilirubin (20 mg/l of bilirubin) and Hb (500 mg/dl) do not influence the results, these experiments have never been published. Still, 20 mg/l of bilirubin (2 mg/dl) is a low concentration to interfere with the results. A larger interference is observed at concentrations above 40 mg/l (4 mg/dl). Hb concentrations of 500 mg/dl (0.5 g/dl) are too low to interfere with GM results and considerable interferences would require Hb concentrations superior to 1,500 mg/dl (1.5 g/dl). Even though we observed an effect of Hb and bilirubin in the concentration curves, in samples of volunteers kept at RT, the alteration in Hb/bilirubin values was not sufficient to cause a change in GM-ODI, both in GM-positive and GM-negative samples. Although we have not found differences in GM values in positive serum samples, the fact that we spiked samples of healthy volunteers with negative GM to simulate the positivity was possibly an important limitation of this study.
In order to facilitate the interpretation of GM results in the presence of severe hemolysis or marked hyperbilirubinemia, we suggest recollecting samples in these specific cases. Also, a short note should be presented for clinicians explaining the impact of Hb and bilirubin in GM results.
This study provides some important information to facilitate clinical laboratories to organize the logistics of GM testing. In particular, we now know that GM readings are not affected by storage of samples for up to 5 days at RT. Moreover, jaundice may have an influence on GM readings in individuals who are already positive for GM, reducing GM-ODI by up to 44%. Still, Hb may have an influence on GM readings in individuals who are GM-negative, by increasing GM-ODI by up to 42%. These data may be clinically useful when interpreting GM results in patients at risk for IA.
